Skip to main content
SpringerLink
Log in

Biosimilar gap discounts in USA may not reduce OOP costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Yazdany J, et al. Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. Journal of the American Medical Association : 4 Sep 2018. Available from: URL: http://dx.doi.org/10.1001/jama.2018.7316

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biosimilar gap discounts in USA may not reduce OOP costs. PharmacoEcon Outcomes News 812, 9 (2018). https://doi.org/10.1007/s40274-018-5276-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5276-5

Search

Navigation